|
Post by JHam on Jul 30, 2014 19:37:45 GMT
The CEO tweeted the other day that we could expect a blog soon recapping what Dr. pierce said at the recent conference. Not sure if that will be a pps mover, but there should be some little juicy bits of info in there. He also mentioned that they would be "updating" their future milestones on the website.
|
|
|
Post by dayanand33 on Jul 31, 2014 11:16:38 GMT
I read through some of the posts on the yahoo forum. You were so right about this being a cult stock, just like ACTC. It was a deja vu experience reading through the posts.
|
|
|
Post by JHam on Jul 31, 2014 14:12:48 GMT
Yeah, that part about it frightens me a tad. However, the one reason why I feel comfortable is that my cost average is below $.50, while most of those posting on Yahoo bought a majority of their shares on the run-up to the mid $.90's earlier this year. It's comparable to someone just learning about ACTC recently and buying when it was in the $.05's the other day. Of course that person is going to be more patient and feel better since they are averaged near the current bottom, and haven't been subjected to the recent downfall.
|
|
|
Post by JHam on Jul 31, 2014 18:42:03 GMT
Yep, i couldn't help myself and added some more at $.436. I am probably done for now, unless it dips below $.40.
|
|
|
Post by JHam on Jul 31, 2014 19:12:11 GMT
Here's an interesting blog from Dr. Pierce from a few months ago. It's almost like all of this happened backwards for ONCS. They basically stumbled upon this treatment by accident, realized it was pretty effective in patients, and are now trying to figure out how it exactly works. I imagine potential partners want to have a better idea of how the science is working before throwing out big numbers: oncosec.com/dr-pierce-combination-therapies/“Let’s talk about the need for combinatorial approaches in oncology therapy – in particular, for immunotherapies.”
On Tumor Immune EvasionTumors deploy multiple parallel mechanisms that synergize – meaning that they work together to get more bang for their buck. In this way, tumors are able to subvert the immune response and protect themselves from being eradicated by the immune system. Thus, we need to similarly deploy multiple parallel synergistic mechanisms to re-program the immune response – to re-hijack it from tumors. It is very rare that you find a patient with a tumor that has a dominant immune checkpoint – where you can simply reverse that one mechanism and see an effect. To put it frankly, we need to move towards combination approaches in immunotherapy. On MonotherapiesIn the past, if a drug didn’t have a measurable effect as a monotherapy it would often be dead in the water. I call this ‘monotherapistic fetishism’. We need to put this in the past. With our ImmunoPulse gene-electro therapy (GET) using IL-12 in melanoma patients, luckily, we have seen an effect. Frankly, we are surprised by how much of a monotherapy effect we are seeing from electroporation of IL-12 in our melanoma patients – but that is a great problem to have. Pushing Through Immune CheckpointsWe are working on trying to understand why it is that IL-12 is driving the immune response strongly enough to push through the PD-1 checkpoint. By that, I mean – you would expect that if IL-12 is driving the generation of tumor-infiltrating lymphocytes (TIL’s), and the TIL’s come into the tumor, you should see an up-regulation of PD-L1. This would then turn off the PD-1 checkpoint on the T-cells and turn off the immune response. In a significant number of patients, we are blowing right through the PD-1 checkpoint and we don’t quite understand how that is happening with IL-12. But like I said, that is a great problem to have.
|
|
|
Post by happyjawa on Jul 31, 2014 20:23:09 GMT
I read through some of the posts on the yahoo forum. You were so right about this being a cult stock, just like ACTC. It was a deja vu experience reading through the posts. You should have been invested when the stock went from .30 to .90. People were freaking out and expected every press release to catapult the stock to 3.00. It's a promising biotech company, but it's still an early stage biotech and people expected to make millions overnight. I'm confident about their immediate future, but I guess we'll see how their trials go. At least the needless rumors of JV, breakthrough status, and all that bs have ceased outside of the yahoo boards. The CEO has stated that this fall they're going to be releasing a lot more updates regarding staff acquisitions and the evolution of their trials, so I expect that the price will get a good bump in September or October. If nothing else, it could be considered a nice short term play if you want to do the DD and decide if it's worth the risk.
|
|
|
Post by JHam on Jul 31, 2014 20:36:26 GMT
I read through some of the posts on the yahoo forum. You were so right about this being a cult stock, just like ACTC. It was a deja vu experience reading through the posts. You should have been invested when the stock went from .30 to .90. People were freaking out and expected every press release to catapult the stock to 3.00. It's a promising biotech company, but it's still an early stage biotech and people expected to make millions overnight. I'm confident about their immediate future, but I guess we'll see how their trials go. At least the needless rumors of JV, breakthrough status, and all that bs have ceased outside of the yahoo boards. The CEO has stated that this fall they're going to be releasing a lot more updates regarding staff acquisitions and the evolution of their trials, so I expect that the price will get a good bump in September or October. If nothing else, it could be considered a nice short term play if you want to do the DD and decide if it's worth the risk. Thanks for the post and insights happyjawa. Nice to have someone here keeping me grounded. I love Jawa's and love the avatar by the way.
|
|
|
Post by Jimmywho on Jul 31, 2014 20:41:13 GMT
Yep, i couldn't help myself and added some more at $.436. I am probably done for now, unless it dips below $.40. My order filled at .435, looks like a good entry point.
|
|
|
Post by JHam on Jul 31, 2014 20:50:54 GMT
Yep, i couldn't help myself and added some more at $.436. I am probably done for now, unless it dips below $.40. My order filled at .435, looks like a good entry point. Well it is the low of the past few months jimmywho, so nice job. This one is definitely high risk, anything could really happen at this point. I still expect some volatility in the near term. Prayers to anyone who follows me into a stock
|
|
|
Post by Jimmywho on Jul 31, 2014 20:55:07 GMT
Can't be any worst then my horses, ADXS and ACTC . Need a winner to buy a couple happy meals.
|
|
|
Post by RLC on Aug 1, 2014 18:56:12 GMT
Yep, i couldn't help myself and added some more at $.436. I am probably done for now, unless it dips below $.40. I thought about it too but am wanting to keep some funds in reserve with some other things playing out in other companies right now (ACTC being one). I'm averaged in at about .47/share right now, but if this dips below $0.40, I think I'll have to make another purchase. Still feel very confident about this one after doing some further DD and appreciate the tip JHam!
|
|
|
Post by JHam on Aug 4, 2014 14:35:49 GMT
Is this fun or what? Whoever has been shorting this thing since the mid $.90's has made a killing over the last few months. I figured we were nearing the bottom around the mid $.50's which is why I opened a position. Until we get news on trial results or news on Phase IIb though I see this continuing to trend down. I probably sound crazy, but I still feel comfortable averaging down.
|
|
|
Post by actcfan on Aug 4, 2014 17:12:17 GMT
alright, i finally stepped into this thing. bought 25% of a position at .405, likely add if it continues to drift downward.
|
|
|
Post by JHam on Aug 4, 2014 17:27:09 GMT
alright, i finally stepped into this thing. bought 25% of a position at .405, likely add if it continues to drift downward. That is a nice low buy actcfan. The market cap is below $100M now and in my opinion is well into oversold territory. It could very well continue to go lower, but at some point it, as long as they have some good news to report, hopefully the tide will start to change in the near future. Good luck to all of us.
|
|
|
Post by JHam on Aug 4, 2014 17:47:25 GMT
Now under $.40. For those who are uncomfortable holding a stock in the red this may not be the stock for you. Definite tree shaking going on now.
|
|
|
Post by lanzapaste on Aug 4, 2014 17:51:43 GMT
Interesting that they raised $16M back in early June at a price of $.71
Do you know what ONCS' burn rate is JHam?
|
|
|
Post by JHam on Aug 4, 2014 20:05:46 GMT
Interesting that they raised $16M back in early June at a price of $.71 Do you know what ONCS' burn rate is JHam? Yeah and they still haven't made public who the the main investor(s)? from the deal was. Whoever it was though, they must not be too thrilled at the moment. The burn rate has been roughly $600-800K a month, but I expect that to increase from here on out as they continue to rev up for the next Phases for a few trials and expand operations/amount of employees on payroll. They had $24M cash on hand in May. Add the $16M raised in June and they should have somewhere around $40M at the moment. Phase IIb is not going to be cheap, but they should have enough to get them through it and hopefully most of Phase III for Melanoma when that starts up in the future.
|
|
|
Post by RLC on Aug 4, 2014 21:17:23 GMT
Is this fun or what? Whoever has been shorting this thing since the mid $.90's has made a killing over the last few months. I figured we were nearing the bottom around the mid $.50's which is why I opened a position. Until we get news on trial results or news on Phase IIb though I see this continuing to trend down. I probably sound crazy, but I still feel comfortable averaging down. Not concerned at all yet, especially considering this move lower hasn't been caused by anything of real substance. If it continues to go lower I will definitely average down. Currently in around .46 average. The more reading I do on PD-1 / PD-L1 and the basis behind ONCS's platform, the more excited I get about holding shares of this company...
|
|
|
Post by actcfan on Aug 5, 2014 17:38:37 GMT
ouch, this thing is having a tough time..
|
|
|
Post by jckrdu on Aug 5, 2014 17:50:58 GMT
ouch, this thing is having a tough time.. Small biotech's are at risk if we do get the overdue market correction. The combination of an anticipated market correction and Yellen's negative comments a few weeks ago stating that the biotech sector was over-valued (words to that effect) could be having some impacts.
|
|